demplatin pegraglumer

a cisplatin-based micellar formulation for treating cancer; structure in first source

Also Known As:

NC 6004; NC-6004; NC6004

Networked: 10 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organometallic Compounds: 64
  - Organoplatinum Compounds
    - demplatin pegraglumer: 10
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Polyglutamic Acid: 124
    - demplatin pegraglumer: 10
- Amino Acids: 30675
  - Acidic Amino Acids: 44
    - Glutamates: 45
      - Polyglutamic Acid: 124
        demplatin pegraglumer: 10
  - Dicarboxylic Amino Acids: 20
    - Glutamates: 45
      - Polyglutamic Acid: 124
        demplatin pegraglumer: 10

Experts

1.	Bobe, Iulian: 2 articles (08/2020 - 01/2018)
2.	Osada, Atsushi: 2 articles (08/2020 - 01/2018)
3.	Masada, Atsuhiro: 2 articles (01/2018 - 01/2017)
4.	Kataoka, Kazunori: 2 articles (12/2017 - 03/2013)
5.	Hamaguchi, Tetsuya: 2 articles (01/2017 - 12/2016)
6.	Matsumura, Yasuhiro: 2 articles (12/2016 - 06/2014)
7.	Cerea, Giulio: 1 article (08/2020)
8.	Ciuleanu, Tudor-Eliade: 1 article (08/2020)
9.	Croitoru, Adina: 1 article (08/2020)
10.	Koralewski, Piotr: 1 article (08/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Twelve patients with advanced solid tumors received 60 or 90 mg/m2 NC-6004. " 01/01/2017 - "This study was an open-label phase I study to confirm the safety and tolerability of NC-6004 in combination with gemcitabine in Japanese patients with advanced solid tumors and to assess the PK effects of NC-6004 monotherapy. " 01/01/2017 - "NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis." 08/18/2020 - "NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. " 01/01/2018 - " Design: Patients with advanced solid tumors received NC-6004 at 60 to 180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/18/2020 - "Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patients. "
3.	Urinary Bladder Neoplasms (Bladder Cancer) 08/18/2020 - "A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer." 08/18/2020 - "Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patients. "
4.	Biliary Tract Neoplasms (Biliary Tract Cancer) 08/18/2020 - "Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patients. "
5.	Squamous Cell Carcinoma of Head and Neck 03/01/2013 - "The present study was designed to evaluate the efficacy and safety of NC-6004 for oral squamous cell carcinoma. " 03/01/2013 - "Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma."

Related Drugs and Biologics

1.	Micelles
2.	NC-4016
3.	Gemcitabine
4.	Cisplatin (Platino)
5.	NK105
6.	Peptides (Polypeptides)
7.	paclitaxel poliglumex (XYOTAX)
8.	NK911
9.	Epirubicin (Ellence)
10.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)